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Dexmedetomidine is a highly selective alpha-2 adrenergic agonist that provides 
sedation, anxiolysis, and analgesia without respiratory depression. This study was 
performed to determine whether it has any advantage over midazolam for intravenous 
sedation during dental surgery under local anaesthesia. 
 
Methods 
The study was randomized and double-blind. Sixty patients received either 
dexmedetomidine (up to 1 µg kg-1) or midazolam (up to 5 mg). The drug was infused 
until the Ramsay Sedation Score reached 4 or the maximum dose had been 
administered. Intraoperative vital signs and adverse events were recorded. Numerical 
rating pain scores and analgesic consumption were charted for 3 days after surgery. 
The pre- and post-operative Mini Mental State Examination (MMSE) scores were 




Sedation was achieved by median [range] doses of 47 µg [25-76] or 0.88 µg kg-1 [0.6-
1.0] dexmedetomidine, and 3.6 mg [1.9-5.0] or 0.07 mg kg-1 [0.017-0.12] midazolam. 
SpO2 < 90% occurred in 6 patients (20%) who received dexmedetomidine and 4 
patients (13%) who received midazolam (P = 0.488). There was no significant 
difference in respiratory rate. Heart rate and blood pressure were lower in the 
dexmedetomidine group during surgery. Patients' and surgeons' satisfaction, pain 
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scores and MMSE scores did not differ significantly between groups. Midazolam was 
associated with greater amnesia. 
 
Conclusions 
Dexmedetomidine produces comparable sedation to midazolam with a lower heart 
rate and blood pressure but less amnesia. No additional analgesic effect of 
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Midazolam is commonly used as an intravenous sedative agent for dental procedures. 
It has a fast onset and rapid recovery, but after repeated administration, prolongation 
of sedation and hangover effects due to the relatively long half-life of midazolam and 
its metabolites are possible.1 Moreover, it depresses the ventilatory response to carbon 
dioxide and results in respiratory depression.2 3 Some patients may also develop 
disinhibition and/or disorientation and not comply with treatment.4 
 
Dexmedetomidine is an alpha-2 agonist which acts on adrenoceptors in many tissues 
including the nervous, cardiovascular and respiratory systems.5 6 The site of action in 
the central nervous system is at the locus coeruleus, where it induces 
electroencephalographic activity similar to natural sleep. The drug also reduces 
catecholamine secretion, thereby reducing stress and leading to a modest (10-20%) 
reduction in heart rate and blood pressure, which may be particularly beneficial in 
patients with cardiovascular disease.7 Unlike midazolam, dexmedetomidine does not 
affect the ventilatory response to carbon dioxide.8 9 In addition to sedation, it also 
produces analgesia,10 11 which could potentially alleviate pain after tooth extraction. 
Such a pharmacodynamic profile may have an advantage over midazolam for dental 
sedation. Therefore, we conducted this study to compare the sedative effects of 





This was a randomized, double-blind trial and the protocol was approved by our local 
Institutional Review Board. Eligibility for subject recruitment included all American 
Society of Anesthesiologists (ASA) physical status I or II patients aged between 18 to 
50 years of age, with asymptomatic impacted third molar scheduled for unilateral 
extraction under local anaesthesia and intravenous sedation. Exclusion criteria 
included clinical history or electrocardiographic evidence of heart block, ischaemic 
heart disease, asthma, sleep apnoea syndrome, impaired liver, renal or mental function, 
alcohol consumption in excess of 28 units per week, and those who regularly used or 
had known allergy to dexmedetomidine, midazolam, paracetamol or 
dextropropoxyphene. 
 
After obtaining written informed consent, patients' demographic data were collected 
and a baseline Mini Mental State Examination (MMSE) was performed.12 Patients 
were then randomly allocated to receive dexmedetomidine (Group D) or midazolam 
(Group M) for intravenous sedation. A computer generated random sequence, based 
on blocks of 4 was used for the drug allocation and was prepared by the statistician 
who was unaware of the clinical nature of the study. The sedation drug was prepared 
by an anaesthesiologist who did not participate in patient management or data 
collection. Either dexmedetomidine 1 µg kg-1 (Group D) or midazolam 5 mg (Group 
M) was mixed with normal saline to a total volume of 20 mL and this was given to the 
attending anaesthesiologist for administration. Both preparations were clear solutions 





On arrival at the operating theatre, a 22-gauge intravenous cannula was inserted. 
Heart rate, blood pressure, respiratory rate and oxygen saturation (S/5 Anesthesia 
Monitor, Datex-Ohmeda, WI, USA) were recorded every 2 minutes during infusion of 
the study drug and thereafter at 5-minute intervals from the time of commencing 
surgery to the end of recovery. The 20 mL solution of study drug was infused over 10 
minutes at a constant rate. During this period, the patients were assessed every minute 
using the Ramsay Sedation Score (RSS, Appendix 1).13 The infusion was stopped 
either when the RSS reached 4 or the full 20 mL (dexmedetomidine 1 µg kg-1 or 
midazolam 5 mg) had been given, whichever was earlier. Following the drug infusion 
and prior to surgery, 2 pictures were shown to the patients and they were asked to 
remember their contents. 
 
Inferior alveolar nerve block was achieved by infiltrating 2% lignocaine with 1 in 
80,000 adrenaline. Patients were then asked to grade the pain resulting from the 
infiltration of local anaesthesia using a numerical rating scale (NRS) where 0 
corresponds to no pain and 10 is the worst pain imaginable. Unilateral wisdom tooth 
extraction was then performed in the usual manner without any further study 
interventions or intended sedative drug supplementation. Inadequate analgesia was 
treated with infiltration of local anaesthetic into the surgical site. If the oxygen 
saturation decreased to less than 90%, surgery was stopped and the instruments 
removed from the patient's mouth. The patient was prompted to take deep breaths and 
oxygen therapy was administered via nasal cannulae. Surgery resumed when oxygen 
saturation was restored to 90% or above. Upon completion of surgery, patients were 
transferred to the recovery room and monitored for 30 minutes. They were then 
 
 7
transferred back to the general ward if fully conscious and the vital signs including 
heart rate, blood pressure and oxygen saturation were stable. 
 
Following arrival of the patients in the ward, heart rate, blood pressure, oxygen 
saturation and NRS pain scores were assessed hourly for 4 hours. Patients were 
prescribed 2 analgesic tablets, each containing paracetamol 320 mg and 
dextropropoxyphene 32.5 mg (Dolpocetmol, Synco Limited, Hong Kong, China), on 
an as required basis to a maximum of 4 times daily. Two hours after surgery, RSS was 
charted and a second MMSE was performed. After that, patients were asked whether 
they were relaxed during the operation (yes or no) and to grade their overall 
satisfaction with the procedure using NRS (0 being least satisfied and 10 being most 
satisfied). They were asked to choose the type of anaesthetic technique they would 
prefer if undergoing a similar operation in the future (local anaesthesia with sedation 
like this time, or general anaesthesia or local anaesthesia with no sedation). To test for 
amnesia, patients were asked if they were aware of certain events during surgery 
(infiltration of local anaesthetic, use of burs, tooth extraction and suturing), and to 
identify the pictures shown immediately after the infusion of the sedation drug from a 
panel of 12 pictures. Patients were discharged from hospital the next day as is usual in 
this hospital. The oral analgesic regimen described above was prescribed for 3 days 
upon discharge. 
 
The chief dental surgeon was asked to grade the surgical conditions in a 4-point scale 
(good, fair, poor, very poor) and grade their satisfaction with sedation using NRS (0 





The primary outcome measure of this study was patients' satisfaction scores using 
NRS from 0 to 10. Sample size calculation was based on a population standard 
deviation of 1.1, two-sided level of significance at 0.05, and power of test at 0.90.14 
To detect a difference in satisfaction score of 1 between groups, a total of 60 patients 
were recruited. An intention-to-treat model was adopted and all recruited patients 
were included in the data analysis. Statistical analysis was performed using SPSS 14.0 
for Windows (SPSS Inc., IL, USA). Perioperative vital signs were plotted into graphs 
using GraphPad Prism 4.03 (GraphPad Software Inc., CA, USA) and the mean areas 
under curve (during study drug infusion, surgery, recovery and in the ward) were 
compared between groups using Student's t test. Patients' and surgeons' satisfaction 
scores, NRS pain scores and analgesic consumption, and difference in pre- and post-
operative MMSE scores were compared using Mann-Whitney U test. All categorical 
data were analyzed using χ2 test. Time to first analgesic use was compared using log-




Sixty patients were recruited. All of them underwent their planned surgical procedure 
and received the allocated study drug. No assigned patients dropped out of the study. 
The patient characteristics and operation data were similar between the two groups 
(Table 1). Sedation was achieved by median [range] dose of 47 µg [25-76] or 
0.88 µg kg-1 [0.6-1.0] dexmedetomidine in Group D, or 3.6 mg [1.9-5.0] or 
0.07 mg kg-1 [0.017-0.12] midazolam in Group M. Twenty three (77%) Group D 
patients and 24 (80%) Group M patients reached the sedation end point (RSS = 4) 
before or at the time when the maximum dose of study drug was infused. All patients 
in Group D and 28 patients (93%) in Group M had a RSS of 3 or above at the end of 
the study drug infusion. Surgery was very difficult in one patient who developed 
moderate aggressive behaviour after receiving midazolam (RSS = 1). No more 
midazolam was given and the procedure could still be completed after repeated 
reassurance. Another was fully awake, but calm (RSS = 2) despite the maximum dose 
of midazolam. One patient in Group M, who had reached RSS 4 after initial infusion, 
became anxious 30 minutes after surgery started and required a further 1 mg bolus 
dose of midazolam. 
 
All baseline vital signs were similar between groups (P > 0.05, Fig. 1a-b). Heart rate 
decreased significantly after dexmedetomidine infusion and remained lower than 
Group M during the surgical and recovery periods (P < 0.001). While respiratory rates 
were similar between groups, oxygen saturation was lower in Group M during drug 
infusion (P = 0.003), but lower in Group D during surgery (P = 0.03). Oxygen 
desaturation (oxygen saturation lower than 90%) occurred in 6 patients (20%) who 
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received dexmedetomidine and 4 patients (13%) who received midazolam (P = 0.488). 
Oxygen saturations rapidly returned to normal upon treatment. 
 
Intraoperative anxiety levels, patients' and surgeons' satisfaction scores were similar 
between groups and most would choose the same intravenous sedation for a similar 
procedure in the future (Table 2). Surgeons graded the surgical conditions as good in 
29 patients (96%) in Group D and 25 patients (83%) in Group M (P = 0.193). The 
main reason of dissatisfaction was patient movement during the procedure.  Amnesia 
was more profound in patients receiving midazolam (Table 3). After 30 minutes of 
recovery, 13 patients (43%) in Group D and 18 patients (60%) in Group M reached 
RSS of 2. All the patients were cardiovascularly stable in the recovery room. Both 
groups had a similar difference in MMSE scores before and at two hours after surgery 
(P = 0.716).  
 
NRS pain scores during local anaesthetic infiltration, in the ward and at 3 days 
postoperatively were similar (P > 0.05, Fig. 2). Median time to first oral analgesic use 
(187 minutes in Group D versus 185 minutes in Group M, P = 0.903) and analgesic 
consumption during the first 3 days after surgery (P > 0.05, Fig. 3) were also similar 
between groups. Within 3 days postoperatively, both groups had 7 patients (23%) 
reporting dizziness, while nausea and vomiting occurred in 3 patients (10%) in Group 






Significant pharmacogenetic differences exist in sedative drug response resulting in a 
large variation in dose requirements.15 16 Studies shows there is a wide range of 
midazolam blood levels associated with adequate sedation.1 Titration is obviously 
important in order to reduce the risk of over sedation and was part of the protocol of 
this study. The median dose required to achieve adequate sedation was 0.88 µg kg-1 
for dexmedetomidine and 0.07 mg kg-1 for midazolam. Unilateral third molar 
extraction is usually a short 30-minute procedure and, therefore, we did not plan to 
give a supplemental intraoperative bolus or maintenance infusion of the study drugs. 
All patients receiving dexmedetomidine reached RSS of 3 or above immediately after 
the infusion, whereas 2 patients receiving midazolam did not, which infers that the 
safe maximum dose of midazolam we had set was insufficient for some patients, such 
as the one who was still fully alert despite the infusion of 5 mg midazolam. 
Midazolam is well known to sometimes cause patient restlessness and disinhibition 
instead of sedation and this has been referred to as a paradoxical reaction.4 Surgery 
will then become extremely difficult, and patients may even require flumazenil for 
reversal.17 One of our patients, who had RSS of 1 after sedation, became agitated after 
midazolam administration and we suspected this condition. We did not give extra 
midazolam because this can exacerbate the problem. This patient could not recall this 
incident postoperatively. 
 
Dexmedetomidine causes an increase in arterial pressure upon rapid bolus infusion.18 
19 This is due to direct effects on vascular alpha-1 receptors. In our study, this was 
minimized by slower infusion of dexmedetomidine but the time to sedation end point 
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would be longer. Dexmedetomidine then exhibits a modest decrease in blood pressure, 
heart rate and cardiac output.18 19 There was no cardiovascular instability requiring 
intervention in all study patients, suggesting both drugs to be safe in this situation. In 
fact the effects of alpha-2 agonists on the cardiovascular system may be protective in 
high risk patients.20 Midazolam also needs to be given reasonably slowly as it has a 
relatively slow time to peak effect.2 21 Midazolam can cause respiratory depression22 
while dexmedetomidine does not.8 9 However, whilst respiratory rate did not differ 
significantly between the two groups, oxygen desaturation (SaO2 < 90%) did occur in 
both groups. Both drugs reduce muscle tone potentially leading to upper airway 
obstruction and, within the dose range that produces moderate sedation, this may be 
more important than respiratory depression .8 For the patients' safety, we started 
intervention as soon as such events occurred, and all patients responded to verbal 
stimulus and low flow oxygen therapy. 
 
Pain on local anaesthetic infiltration can be a stressful experience and pain after dental 
surgery may be considerable.23 Alpha-2 receptors are abundant in the dorsal horn of 
the spinal cord where they are involved in pain modulation. The analgesic properties 
of dexmedetomidine have been demonstrated in healthy volunteer studies,11 24 but 
there is some controversy over this in clinical practice.25 When it is used 
preoperatively or intraoperatively, the analgesic consumption can be reduced, without 
lowering the pain scores.26-28 In our study, pain during the infiltration of local 
anaesthetic was moderate to severe in both groups (mean NRS pain score over 5). The 
NRS pain scores recorded postoperatively from the first hour to the third day were 
also similar. Furthermore, there was no difference in the time of first oral analgesic 
taken and daily oral analgesic consumption, suggesting no preemptive analgesic effect. 
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Sedation with midazolam has been reported to reduce pain after dental surgery when 
compared with placebo,29 but we felt it was not ethical to have a placebo control 
group in this study. 
 
Amnesia may or may not be an advantage to patients. Some may wish to avoid the 
recall of what may be perceived as the unpleasant experience of dental surgery, but 
many patients do not like this memory loss. It is well known that midazolam has a 
potent anterograde amnesic effect. Hall and colleagues have also demonstrated 
impairment of memory and psychomotor performance with dexmedetomidine 
infusion.11 In the present study, more than half of the patients receiving 
dexmedetomidine remembered the pictures shown at the end of sedation drug infusion, 
but only 2 patients receiving midazolam did so. However, the amnesic effect of 
midazolam rapidly diminished with time and a comparable number of patients in both 
groups could remember the surgical procedures. A few patients who received 
dexmedetomidine recalled the infiltration of local anaesthetic but failed to remember 
the surgical procedure, most likely because the former is a greater stimulus. Similarly, 
the stimulation due to suturing is probably lower. 
 
After surgery, most patients felt comfortable with the sedation with either drug. Both 
groups were highly satisfied with the surgery and expressed a preference for the same 
anaesthetic care (as opposed to general anaesthesia or local anaesthetic alone) in the 
future. Thus, both drugs appear to be equally acceptable to patients, although this 
could really only be truly evaluated with a crossover comparison. Fast recovery is 
desirable after sedation and short surgery, and the sedative effects of both drugs were 
also comparable in this regard. MMSE performance was completely normal within 2 
 
 14
hours which can suggest that they both may be suitable for day-stay surgery. 
Postoperatively, neither drug had an advantage in reducing side effects such as 
dizziness, nausea and vomiting. 
 
In conclusion, dexmedetomidine provides comparable sedation to midazolam for 
unilateral wisdom tooth extraction under local anaesthesia. It is associated with a mild 
reduction in heart rate and blood pressure as opposed to a slight increase with 
midazolam. There is less amnesia but no improvement in analgesia. 
Dexmedetomidine may have an advantage in reducing patient movement. Oxygen 
desaturation can occur with both drugs as a result of loss of airway muscle tone rather 
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The patient characteristics and operative data. 
 
 Dexmedetomidine Midazolam 
 (n = 30) (n = 30) 
Male : Female 9 (30%) : 21 (70%) 9 (30%) : 21 (70%) 
Age (years) 25.5 [20-36] 27.7 [18-47] 
Body weight (kg) 54.3 [37-77] 56.5 [40-109] 
ASA physical status 
 I 29 (97%) 29 (97%) 
 II 1 (3%) 1 (3%) 
Preoperative MMSE score 28.7 [25-30] 28.7 [24-30] 
Duration of surgery (minutes) 21.4 [7-50] 21.1 [8-58] 
 






Comparison of patients’ report on relaxation, preferences on anesthetic method for a 
similar procedure in future, patients’ satisfaction scores and surgeons’ satisfaction 
scores. 
 
  Dexmedetomidine Midazolam P 
  (n = 30) (n = 30) 
Relaxed during surgery 24 (80%) 25 (83%) 0.739 
Preferred the same intravenous  
sedation next time 27 (90%) 26 (87%) 0.688 
Patients’ satisfaction score 9 [8-9] 9 [8-10] 0.988 
Surgeons’ satisfaction score 9 [8-10] 8 [8-10] 0.531 
 





Amnesic effects of dexmedetomidine and midazolam. 
 
Items or procedures recalled Dexmedetomidine Midazolam P 
  (n = 30) (n = 30) 
Pictures shown when sedation was achieved 18 (60%) 2 (7%) < 0.001 
Infiltration of local anesthetics 25 (83%) 13 (43%) 0.001 
Use of burs 22 (73%) 17 (57%) 0.176 
Tooth extraction 22 (73%) 21 (70%) 0.774 
Suturing 17 (57%) 17 (57%) 1.000 
 





Vital signs of patients receiving dexmedetomidine (Group D, denoted by square data 
points ■) and midazolam (Group M, denoted by round data points ●) during study 
drug infusion, surgical procedures, recovery period and in the ward. Data shown are 
mean values with error bars representing one standard deviation. Data points were 
slightly shifted horizontally to avoid overlapping. LA = local anesthetic. (a) Heart rate 
in Group D was significantly lower than Group M at all 4 periods (P < 0.001). 
Compared to Group M, blood pressure in Group D tended to be higher during study 
drug infusion (P = 0.183), but significantly lower during surgery, recovery and in the 
ward (P < 0.001). (b) Respiratory rates were similar between groups (all P > 0.05). 
Oxygen saturation was lower in Group M during study drug infusion (P = 0.003), 
lower in Group D during surgery (P = 0.03), and similar during recovery period and 












There was no significant difference between median postoperative (postop) numerical 
rating scale (NRS) pain scores of patients receiving dexmedetomidine and midazolam 







Median postoperative (postop) analgesic consumption of patients receiving 








The Ramsay Sedation Score: 
1. Patient is anxious and agitated or restless, or both 
2. Patient is co-operative, oriented, and tranquil 
3. Patient responds to commands only 
4. Patient exhibits brisk response to light glabellar tap or loud auditory stimulus 
5. Patient exhibits a sluggish response to light glabellar tap or loud auditory stimulus 
6. Patient exhibits no response 
 
 
